<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37258036</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Remission of lupus nephritis: the trajectory of histological response in successfully treated patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000932</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2023-000932</ELocationID><Abstract><AbstractText Label="OBJECTIVE">This study investigated changes in kidney histology over time in patients with lupus nephritis (LN) undergoing immunosuppressive treatment.</AbstractText><AbstractText Label="METHODS">Patients with proliferative&#xb1;membranous&#x2009;LN were studied. After a diagnostic kidney biopsy (Bx1), patients had protocol biopsy 2 (Bx2) at 9 (6-15) months and protocol biopsy 3 (Bx3) at 42 (28-67) months. Kidney histological activity and chronicity indices (AI, CI) were measured.</AbstractText><AbstractText Label="RESULTS">AI declined in a biphasic fashion, falling rapidly between Bx1 and Bx2 and then more slowly between Bx2 and Bx3. Patients were divided into those who achieved histological remission, defined as an AI=0 at Bx3 (group 1), and those with persistent histological activity (AI &gt;0) at Bx3 (group 2). The early decline in AI was 1.6 times greater (95% CI 1.30, 1.91) in group 1 than group 2 (p=0.01). Between Bx2 and Bx3, the AI decline was 2.19-fold greater (95%&#x2009;CI 2.09, 2.29) in group 1 versus group 2 (p=7.34&#xd7;10<sup>-5</sup>). Individual histological components of the AI resolved at different rates. Inflammatory lesions like glomerular crescents, karyorrhexis and necrosis mostly resolved by Bx2, whereas endocapillary hypercellularity, subendothelial hyaline deposits and interstitial inflammation resolved slowly, accounting for residual histological activity at biopsy 3 in group 2. In contrast, CI increased rapidly, by 0.15 units/month between Bx1 and Bx2, then plateaued. There were no differences in the rate of accumulation of chronic damage between group 1 and group 2. The increase in CI was significantly related to the severity of glomerular crescents (p=0.044), subendothelial hyaline deposits (p=0.002) and interstitial inflammation (p=0.015) at Bx1.</AbstractText><AbstractText Label="CONCLUSIONS">LN histological activity takes months to years to resolve, providing a rationale for the need of long-term, well-tolerated maintenance immunosuppression. Despite responding, LN kidneys accrue chronic damage early during treatment. This finding provides an explanation for the association of chronic progressive kidney disease with recurrent episodes of LN.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Malvar</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nephrology Unit, Hospital Fernandez, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Alberton</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Nephrology Unit, Hospital Fernandez, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lococo</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Nephrology Unit, Hospital Fernandez, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lourenco</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nephrology Unit, Hospital Fernandez, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Joaquin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nephrology Unit, Hospital Fernandez, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burna</LastName><ForeName>Lucrecia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Nephrology Unit, Hospital Fernandez, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besso</LastName><ForeName>Celeste</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nephrology Unit, Hospital Fernandez, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nephrology Unit, Hospital Fernandez, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagaraja</LastName><ForeName>Haikady N</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khatiwada</LastName><ForeName>Aastha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, National Jewish Health, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Bethany</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovin</LastName><ForeName>Brad</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5639-0210</Identifier><AffiliationInfo><Affiliation>Internal Medicine/Nephrology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA Brad.Rovin@osumc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AR071947</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007678" MajorTopicYN="N">Kidney Glomerulus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37258036</ArticleId><ArticleId IdType="pmc">PMC10255076</ArticleId><ArticleId IdType="doi">10.1136/lupus-2023-000932</ArticleId><ArticleId IdType="pii">10/1/e000932</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, et al. . Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713&#x2013;23. 10.1136/annrheumdis-2020-216924</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group . KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 2021;100:S1&#x2013;276. 10.1016/j.kint.2021.05.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.021</ArticleId><ArticleId IdType="pubmed">34556256</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinley A, Park E, Spetie D, et al. . Oral cyclophosphamide for lupus glomerulonephritis: an under-utilized therapeutic option. Clin J Am Soc Nephrol 2009;4:1754&#x2013;60. 10.2215/CJN.02670409</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.02670409</ArticleId><ArticleId IdType="pmc">PMC2774957</ArticleId><ArticleId IdType="pubmed">19729427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopp JB, Factor VM, Mozes M, et al. . Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996;74:991&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">8667617</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond JR, Anderson S. Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition. Am J Pathol 1990;137:1323&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877718</ArticleId><ArticleId IdType="pubmed">2260622</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvar A, Pirruccio P, Alberton V, et al. . Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant 2017;32:1338&#x2013;44. 10.1093/ndt/gfv296</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfv296</ArticleId><ArticleId IdType="pmc">PMC5837387</ArticleId><ArticleId IdType="pubmed">26250434</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvar A, Alberton V, Lococo B, et al. . Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int 2020;97:156&#x2013;62. 10.1016/j.kint.2019.07.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2019.07.018</ArticleId><ArticleId IdType="pubmed">31685314</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I, Adamichou C, Aydin S, et al. . Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology (Oxford) 2020;59:3424&#x2013;34. 10.1093/rheumatology/keaa129</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa129</ArticleId><ArticleId IdType="pubmed">32353879</ArticleId></ArticleIdList></Reference><Reference><Citation>Zickert A, Sundelin B, Svenungsson E, et al. . Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med 2014;1:e000018. 10.1136/lupus-2014-000018</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2014-000018</ArticleId><ArticleId IdType="pmc">PMC4213828</ArticleId><ArticleId IdType="pubmed">25379188</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa M, Azzato F, Toblli JE, et al. . A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int 2018;94:788&#x2013;94. 10.1016/j.kint.2018.05.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2018.05.021</ArticleId><ArticleId IdType="pubmed">30045812</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders H-J, Saxena R, Zhao M-H, et al. . Lupus nephritis. Nat Rev Dis Primers 2020;6:7. 10.1038/s41572-019-0141-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D&#x2019;agati VD, Schwartz MM, et al. . The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney International 2004;65:521&#x2013;30. 10.1111/j.1523-1755.2004.00443.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema IM, Wilhelmus S, Alpers CE, et al. . Revision of the International society of Nephrology/renal pathology society classification of lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and Chronicity indices. Kidney International 2018;93:789&#x2013;96. 10.1016/j.kint.2017.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, et al. . Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020;383:1117&#x2013;28. 10.1056/NEJMoa2001180</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Teng YKO, Ginzler EM, et al. . Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2021;397:2070&#x2013;80. 10.1016/S0140-6736(21)00578-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId><ArticleId IdType="pubmed">33971155</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Nagaraja HN, Hebert L, et al. . Renal flare as a predictor of incident and progressive chronic kidney disease in patients with lupus nephritis. Clin J Am Soc Nephrol 2014;9:279&#x2013;84. 10.2215/CJN.05040513</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.05040513</ArticleId><ArticleId IdType="pmc">PMC3913239</ArticleId><ArticleId IdType="pubmed">24262502</ArticleId></ArticleIdList></Reference><Reference><Citation>Enfrein A, Pirson V, Le Guern V, et al. . Worse long-term renal outcome of lupus nephritis patients of African descent living in Europe. RMD Open 2022;8:e002386. 10.1136/rmdopen-2022-002386</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002386</ArticleId><ArticleId IdType="pmc">PMC9608524</ArticleId><ArticleId IdType="pubmed">36283757</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Arias AA, M&#xe1;rquez-Macedo SE, Pena-Vizcarra OR, et al. . The influence of repeated flares in response to therapy and prognosis in lupus nephritis. Nephrol Dial Transplant 2023;38:884&#x2013;93. 10.1093/ndt/gfac304</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfac304</ArticleId><ArticleId IdType="pubmed">36318456</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>